15 August 2018

An American patent for a new technology that can determine the electrical activation of the heart chambers and measure their mutual delays with the accuracy of milliseconds was obtained by scientists of FNUSA-ICRC, the Institute of Scientific Instruments of the CAS and M&I Praha company. The technology that uses high-frequency components in the ECG signal was discovered primarily by scientists and physicians working in Brno. In practice, it can be used to determine a more effective treatment of patients with failing heart, thereby significantly prolonging the length of their lives. Additionally, the technology enables improved pacemaker settings for ongoing treatment to ensure the best possible performance of the heart as a pump. Its advantage is a simple and non-invasive procedure, also the diagnostics are cheap and easily accessible.

Pavel Leinveber FNUSA-ICRC
Go to top